Resource

With the development of genomic tools, there has been increasing awareness of germline variants associated with cancer predisposition. Maturing technologies, such as next‑generation sequencing (NGS), have made the identification of hereditary cancer (CGx) variants fast and affordable enough for clinical use. Despite these advances, significant challenges remain for high‑complexity CLIA laboratories to adopt CGx. These include domain knowledge of NGS, genomic interpretation of germline variants, production‑level processes in the laboratory to meet turnaround time demands, and the reimbursement landscape. In this webinar, Jeremy Stuart will outline these and other challenges his laboratory has faced as they developed, validated, and established production-level CGx testing.

Speaker:

Jeremy Stuart, PhD, MPH
Chief Scientific Officer and CLIA Laboratory Director
Precision Genetics

Please fill out the short form below to view this recorded webinar.

(*Indicates a mandatory field)

First Name*

Last Name*

Institution*

Telephone

Email*

City*

Country/Region*

I would like to be contacted by a sales representative for a quotation or demonstration of next-generation sequencing solutions from Thermo Fisher Scientific.